Skip to main content
OpenTrials
Completed

NCT Number: NCT00573781

Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism

Professor Matti Uusitupa, University of Kuopio, Department of Clinical Nutrition (www.uku.fi) Docent Matej Oresic, VTT (www.vtt.fi) Ursula Schwab, PhD, Docent, Marjukka Kolehmainen, PhD, Docent, Leena Pulkkinen, PhD, Docent, David Laaksonen, MD, PhD, MPH, Docent, Kaisa Poutanen, DSc (Tech), Research Professor

ABSTRACT

The metabolic syndrome (MS) and type 2 diabetes (T2DM) are the most important health problems worldwide. In Finland the prevalence of T2DM is 12-15% among middle-aged people. The prevalence of less marked disturbances in glucose metabolism and MS is 30-40%. Because MS and T2DM are important risk factors for cardiovascular diseases (CVD), the leading cause of death in western countries, all efforts to reverse the epidemic increase in the incidence of MS and T2DM are warranted. The investigators have focused for years on the prevention and non-pharmacological treatment of T2DM and its complications including studies on genetic regulation of glucose and lipid metabolism after dietary modifications. In the investigators' recent projects, the investigators have studied the effects of long-term dietary interventions on gene expression profiles of fat tissue in subjects who are at risk of T2DM. The ultimate goal of these projects has been to identify genes and gene clusters and their biological pathways that respond to dietary modification and modulate glucose and lipid metabolism, and to develop dietary strategies for prevention of T2DM. The main goal of this project is to find nutrition related early biomarkers for progression of MS to T2DM by using modern technologies of systems biology (transcriptomics, metabolomics) of carefully conducted dietary interventions involving subjects with MS. The data will be analysed by using bioinformatics. The investigators reflect these new data to well-known risk factors for T2DM and CVD, e.g., insulin sensitivity, insulin secretion, serum lipids and inflammatory factors among others. In addition to interventions conducted earlier, a new intervention with a whole grain-berry-fish diet and a whole grain diet compared to a control diet with refined foods will be performed. The aim is to increase the investigators' understanding on the synergistic effects of these foods, because the investigators' previous interventions have shown that these individual foods have beneficial effects on glucose and lipid metabolism. On the contrary, diets with refined foods may be harmful in long-term due to its high insulin response, which may through chronic stress lead to both insulin resistance and beta-cell damage.

The significance of this project is to increase understanding of the pathophysiology of MS, T2DM and CVD in physiological, cellular and genetic systems, which may lead to more effective and individualised strategies for treatment and prevention, and better identification of high-risk individuals responsive to specific dietary modifications. Increasing knowledge of dietary factors involved in the progression of MS to T2DM and CVD offers new opportunities to individually tailored diets in the management and prevention of these disorders. The results will also be beneficial for the food industry in developing new functional foods. These results and actions may help delay or even stop the epidemic of MS and T2DM and their negative effect on public health currently seen in Finland and worldwide.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • impaired glucose tolerance (oral glucose tolerance test with 2-h glucose concentration 7,8-11,0 mmol/l) OR
  • impaired fasting glucose fasting plasma glucose concentration 5,6-6,9 mmol/l = IFG)
  • and two of the criteria for metabolic syndrome:
  • BMI 26-39 kg/m2
  • Waist circumference > 102 cm (men) or > 88 cm (women)
  • hypertriglyceridemia (fasting serum triglyceride conc > 1,7 mmol/l),
  • HDL-cholesterol (fasting serum HDL conc < 1,0 mmol/l for men and < 1,3 mmol/l for women)
  • Blood pressure ≥ 130/≥ 85 mmHg

Exclusion criteria

  • BMI > 40 kg/m2
  • fasting serum triglyceride conc > 3.5 mmol/l
  • fasting serum cholesterol > 8 mmol/l
  • type 1 or 2 diabetes
  • abnormal liver, kidney or thyroid function
  • large alcohol intake (women >16, men > 24 doses (4cl liquor or equivalent) during week)
  • inflammatory bowel disease
  • disease that prevents participation
  • neuroleptic neuroleptic cortisone medication

Treatment and study plan

Diet with increased intake of rye bread, berries and fish

Dietary Supplement

Dietary modification with commercial food items

Increased intake of whole grain and rye bread

Dietary Supplement

Dietary modification with commercial food items

Control diet with decreased intake of rye bread, berries and fish

Dietary Supplement

Dietary modification with commercial food items

Primary outcomes

  1. Changes in glucose metabolism, changes in transcriptomic and metabolomic profiles

    Time frame: By 2010

Secondary outcomes

  1. Interaction between the diet and genetic factors within treatment groups

    Time frame: By 2010

Sponsors and collaborators

Lead sponsor

Marjukka Kolehmainen

Other

Collaborators

  • VTT Technical Research Centre, Finland
  • Wageningen University

Registry information

Official study title

Systems Biology Approach to Understand Dietary Modulation of Gene Expression and Metabolic Pathways in Subjects With Abnormal Glucose Metabolism (Sysdimet)

Acronym: Sysdimet

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Dec 14, 2007
Registry last updated
Apr 17, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.